Clinigen Group plc Form 8 (OPD) - Clinigen Group plc (6442V)
December 14 2021 - 10:36AM
UK Regulatory
TIDMCLIN
RNS Number : 6442V
Clinigen Group plc
14 December 2021
FORM 8 (OPD)
PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER
Rule 8.2 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: Clinigen Group plc
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): N/A
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s),
settlor and beneficiaries must be named.
-------------------
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Clinigen Group plc
Use a separate form for each offeror/offeree
-------------------
(d) Is the discloser the offeror or the offeree? Offeree
-------------------
(e) Date position held: 14 December 2021
The latest practicable date prior to the disclosure
-------------------
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect N/A
of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
-------------------
2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for
each additional class of relevant security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates
Class of relevant security: Ordinary shares of GBP0.001 each
Interests Short positions
-------------------- ------------------
Number % Number %
-------------- ---- ------------- ---
(1) Relevant securities owned and/or controlled: Nil - Nil -
-------------- ---- ------------- ---
(2) Cash-settled derivatives: Nil - Nil -
-------------- ---- ------------- ---
(3) Stock-settled derivatives (including options) and agreements to Nil - Nil -
purchase/sell:
-------------- ---- ------------- ---
Nil - Nil -
TOTAL:
-------------- ---- ------------- ---
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
(b) Rights to subscribe for new securities
Class of relevant security in relation to which subscription right exists: Nil
Details, including nature of the rights concerned and relevant percentages: N/A
----
3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE
Details of any interests, short positions and rights to subscribe (including directors' and
other employee options) of any person acting in concert with the party to the offer making
the disclosure:
(a) Interests held by the directors of Clinigen Group plc (and their related persons if applicable)
Director Number of Ordinary Percentage of total
Shares held issued share capital
(to two decimal places)
Elmar Schnee 10,000 0.01
------------------- -------------------------
Shaun Chilton 330,044 0.25
------------------- -------------------------
Anne Hyland 11,858 0.01
------------------- -------------------------
Alan Boyd 7,000 0.01
------------------- -------------------------
Total: 358,902 0.27
------------------- -------------------------
(b) Options and awards held by directors of Clinigen Group plc in its ordinary shares:
Long Term Incentive Plan
Maximum number
of Clinigen
Clinigen Shares awarded
Director (ordinary shares) Date of grant Exercise Period
Shaun Chilton 43,811 19 June 2015 25 September
2017 -
18 June 2025
------------------- ----------------- ------------------
34,452 30 November 2015 30 November 2018
-
29 November 2025
------------------- ----------------- ------------------
159,893 21 October 2016 21 October 2019
-
20 October 2026
------------------- ----------------- ------------------
20,943 16 October 2017 15 October 2020
-
15 October 2027
------------------- ----------------- ------------------
26,178 6 November 2017 5 November 2020
-
5 November 2027
------------------- ----------------- ------------------
63,604 31 October 2018 31 October 2021
-
30 October 2028
------------------- ----------------- ------------------
95,238 28 October 2019 28 October 2022
-
27 October 2029
------------------- ----------------- ------------------
127,442 22 October 2020 27 October 2023
-
22 October 2030
------------------- ----------------- ------------------
118,110 1 October 2021 30 September
2024 -
29 September
2031
------------------- ----------------- ------------------
Total: 689,671 - -
------------------- ----------------- ------------------
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain
from dealing entered into by the party to the offer making the disclosure or any person acting
in concert with it:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the party
to the offer making the disclosure, or any person acting in concert with it, and any other
person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
(c) Attachments
Are any Supplemental Forms attached?
Supplemental Form 8 (Open Positions) NO
Supplemental Form 8 (SBL) NO
---
Date of disclosure: 14 December 2021
Contact name: Amanda Miller
-----------------
Telephone number: 07764 784305
-----------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service.
The Panel's Market Surveillance Unit is available for
consultation in relation to the Code's disclosure requirements on
+44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FEEUSUNRABUUAAA
(END) Dow Jones Newswires
December 14, 2021 11:36 ET (16:36 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From Jul 2023 to Jul 2024
